Patents by Inventor Ronald G. Crystal

Ronald G. Crystal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12122844
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: October 22, 2024
    Assignees: Cornell University, Memorial Sloan-Kettering Cancer Center
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
  • Publication number: 20240307517
    Abstract: The invention is directed to fentanyl analogues and a conjugate comprising same, as well as a method of inducing an immune response against fentanyl.
    Type: Application
    Filed: May 10, 2022
    Publication date: September 19, 2024
    Applicant: Cornell University
    Inventors: Ronald G. Crystal, Stephen Kaminsky, Tristan H. Lambert, Dolan Sondhi, Bishnu De, Philip L. Leopold, Andrew Thomas Holm
  • Patent number: 12031144
    Abstract: A gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency is provided comprising a plasmid or viral, e.g., an AAV, vector coding for an elastase- or cathepsin G-inhibiting, oxidation-resistant human AAT with a substitution at, for example, Met358 and/or Met351.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: July 9, 2024
    Assignee: Cornell University
    Inventors: Ronald G. Crystal, Katie Stiles, Meredith Sosulski, Stephen M. Kaminsky, Dolan Sondhi, Bishnu De, Jonathan Rosenberg
  • Patent number: 12024568
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: July 2, 2024
    Assignees: Cornell University, Memorial Sloan-Kettering Cancer Center
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
  • Publication number: 20230405148
    Abstract: Compositions and methods to prevent, inhibit or treat a disease or disorder associated with expression of APOE4 in a mammal are provided.
    Type: Application
    Filed: October 16, 2020
    Publication date: December 21, 2023
    Inventors: Ronald G. Crystal et al., Katie M Stiles
  • Patent number: 11821009
    Abstract: Modified AAV vectors and uses thereof are provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: November 21, 2023
    Assignee: Cornell University
    Inventors: Ronald G. Crystal, Katie Stiles
  • Publication number: 20230313223
    Abstract: Compositions having nucleic acid sequences for regulating expression from gene therapy vectors, and methods of using the compositions, are provided.
    Type: Application
    Filed: October 15, 2020
    Publication date: October 5, 2023
    Inventors: Ronald G. CRYSTAL, Katie M. STILES
  • Publication number: 20230044351
    Abstract: A gene therapy vector comprising an expression cassette coding for a mammalian apolipoprotein E that has a residue other than arginine at at least one of positions 112, 136, or 158, but is not a mammalian apolipoprotein E that has R112, R136 and R158 or a mammalian apolipoprotein E that has C112, R136 and C158, or coding for an antibody that binds to APOE4 or disrupts the binding of APOE to heparan sulfate proteoglycans, and methods of using the vector, are provided.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 9, 2023
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Katie M Stiles, Dolan Sondhi
  • Publication number: 20220088143
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Application
    Filed: December 9, 2021
    Publication date: March 24, 2022
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison
  • Publication number: 20220090128
    Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).
    Type: Application
    Filed: April 5, 2021
    Publication date: March 24, 2022
    Inventors: Hélène Monique PUCCIO, Patrick AUBOURG, Ronald G. CRYSTAL, Pierre BOUGNERES
  • Publication number: 20210381002
    Abstract: Compositions and methods for anti-oxidant therapy are provided.
    Type: Application
    Filed: April 3, 2019
    Publication date: December 9, 2021
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Christiana Salami
  • Publication number: 20210340565
    Abstract: The present invention relates to a method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence of a gene that can restore energy failure. More particularly, the invention relates to a method for preventing or treating a cardiomyopathy associated with Friedreich ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a frataxin (FXN) encoding nucleic acid.
    Type: Application
    Filed: November 24, 2020
    Publication date: November 4, 2021
    Inventors: Helene Monique PUCCIO, Patrick AUBOURG, Ronald G. CRYSTAL, Pierre BOUGNERES
  • Publication number: 20210171656
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Application
    Filed: July 13, 2020
    Publication date: June 10, 2021
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
  • Patent number: 10946094
    Abstract: The invention provides a method of treating ovarian cancer in a patient by administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: March 16, 2021
    Assignee: Cornell University
    Inventors: Ronald G. Crystal, Arash Rafii Tabrizi
  • Publication number: 20200330608
    Abstract: Compositions and methods for eosinophilia in a mammal are provided. In one embodiment, the composition is a viral gene therapy vector, and a single dose of the vector reduces increased lumbers of eosinophils in a mammal.
    Type: Application
    Filed: December 28, 2018
    Publication date: October 22, 2020
    Inventors: Ronald G. Crystal, Odeiya E. Pagovich, Katie Stiles
  • Publication number: 20200172605
    Abstract: Gene therapy compositions and methods to inhibit or treat neurodegenerative diseases, e.g., Alzheimer's disease, are provided.
    Type: Application
    Filed: October 26, 2019
    Publication date: June 4, 2020
    Inventors: Ronald G. Crystal, Steven M. Paul
  • Publication number: 20200157564
    Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).
    Type: Application
    Filed: May 14, 2019
    Publication date: May 21, 2020
    Inventors: Hélène Monique PUCCIO, Patrick AUBORG, Ronald G. CRYSTAL, Pierre BOUGNERES
  • Publication number: 20200102575
    Abstract: A gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency is provided comprising a plasmid or viral, e.g., an AAV, vector coding for an elastase- or cathepsin G-inhibiting, oxidation-resistant human AAT with a substitution at, for example, Met358 and/or Met351.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 2, 2020
    Inventors: Ronald G. Crystal, Katie Stiles, Meredith Sosulski, Stephen M. Kaminsky, Dolan Sondhi, Bishnu De, Jonathan Rosenberg
  • Publication number: 20200032220
    Abstract: Modified AAV vectors and uses thereof are provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: January 30, 2020
    Inventors: Ronald G. Crystal, Katie Stiles
  • Publication number: 20190358297
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison